The most recent study enrolled participants between the ages of 18 and 80 and found that antibody responses were induced in all recipients. Participants aged 60 and over responded more slowly and took 42 days to detect antibodies in all recipients compared to 28 days for participants aged 18 to 59 years.
The study was not designed to evaluate the effectiveness of the vaccine. Therefore, it cannot be said whether the antibody responses induced by the vaccine, called BBIBP-CorV, are sufficient to protect people from SARS-CoV-2 infection.
The authors also found that the interpretation of the results of this study was limited by the short follow-up period.
There are currently 42 vaccines against COVID-19 in clinical trials, according to The Lancet. Vaccine candidates in clinical trials vary in nature and include DNA plasmid vaccines, inactivated virus vaccines, adenovirus vector vaccines, RNA vaccines, protein subunit vaccines, and particle virus-like vaccines. Some of these have already been shown to be safe in early clinical studies and can trigger immune responses.
“Our results show that a booster shot is necessary to get the best antibody responses against SARS-CoV-2 and could be important for protection. This provides useful information for a phase 3 study, ”said Yang Xiaoming, one of the authors and professor of the study at the Beijing Institute of Biological Products.
These were the details of the news. Preliminary results show China’s COVID-19 vaccine candidate is safe: The Lancet for the day. We hope we managed to give you all the details and information. To stay up to date with all the news, you can subscribe to the notification system or one of our various systems to receive everything new.
It’s also worth noting that the original news has been published and is available at de24.news. Today’s editorial team at AlKhaleej has confirmed this and it has been changed. It may have been retransmitted or cited in full. You can read it and follow this news from the main source.
These were the details of the news Preliminary results show China’s COVID-19 vaccine candidate is safe: The Lancet for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.
It is also worth noting that the original news has been published and is available at de24.news and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.